Our Team

COL (ret) George E. Peoples, MD, FACS, is the founder and CEO of LumaBridge (formerly Cancer Insight [CI]) and Trauma Insight (TI). He served 30 years of active duty as a surgeon and research scientist in the military and was founder and director of the Cancer Vaccine Development Program (CVDP). The CVDP has over 20 years of experience in the discovery, development, and clinical testing of cancer vaccines, including 5 that have been licensed for commercial development. In 2014, Dr. Peoples retired from the military and founded CI and TI.

Dr. Peoples serves as a professor of surgery at Uniformed Services University of the Health Sciences and professor (adjunct) of surgical oncology at MD Anderson Cancer Center (MDACC). He is the former chair of the Cancer Care Program at the San Antonio Military Medical Center and the past military director of the United States Military Cancer Institute. He is a graduate of the United States Military Academy at West Point and the Johns Hopkins School of Medicine. He completed his surgical training at Harvard’s Brigham and Women’s Hospital and a surgical oncology fellowship at MDACC. He has written extensively on the immune response to cancer, with over 300 peer-reviewed manuscripts, abstracts, and book chapters.

Amanda Ferrier

Amanda Ferrier is an experienced clinical operations executive who specializes in organizational development and strategic planning through the harmonization of people, processes, and scientific discovery. With over 20 years of global biopharmaceutical experience, she is responsible for overseeing the cohesiveness and efficiency of the LumaBridge operations team and ensuring strategic execution of the clinical drug development lifecycle while addressing increasingly complex client needs and evolving drug development processes.  

Before joining LumaBridge, Ms. Ferrier served in various leadership positions at both CRO and sponsor organizations, where she was instrumental in streamlining operational delivery and spearheading specialized processes such as cell and gene therapy operational strategies and logistics. Her experience spans several therapeutic areas, with a focus on hematology/oncology and rare diseases as well as areas of increasing innovation, such as biomarkers, cell and gene therapies, and vaccines. She also supported CRO global business expansion and Asia-Pacific team development while in these roles.  

Ms. Ferrier began her research career at ILEX Oncology, Inc. (acquired by Genzyme 2004), in San Antonio, Texas, where she was fortunate enough to contribute to the approval of clofarabine (CLOLAR®), the first of over 25 NDAs throughout her career. She is a Registered Nurse, a Certified Project Management Professional (PMP), and a Lean Six Sigma Yellow Belt. Ms. Ferrier holds a bachelor of science from Texas A&M University and another bachelor of science from The University of Texas Health Science Center, and she began MBA coursework from Suffolk University in Boston.

Alexander Stojadinovic, the new CMO of LumaBridge, brings extensive experience in strategic planning, program development, team building, operations, and research and development. He has served as senior medical director in oncology clinical development at GlaxoSmithKline, as medical director of healthcare management services for Amerigroup Texas, and as a consulting surgical oncologist and healthcare executive. He was a founding partner of the Institute for Hyperthermic Regional Perfusion as well as 3rd Curve Healthcare. He was regional director of Bon Secours Cancer Institute in Virginia, and as a surgical oncology consultant, he continues to see patients and operate at Bon Secours Mercy Healthcare System’s Saint Mary’s Hospital.  

Dr. Stojadinovic received his executive education in general management at the Harvard Business School. He completed a physician executive master’s of business administration (PEMBA) at the University of Tennessee, Knoxville, and a master of science in regulatory science at the University of Maryland School of Pharmacy. He is a graduate of the United States Military Academy and the Uniformed Services University of the Health Sciences in Bethesda, Maryland, where he received his medical degree. He was recognized with multiple clinical excellence awards during his general surgical residency at Walter Reed Army Medical Center. While completing his surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC), he became the first recipient of the MSKCC Award for Excellence in Clinical Research. He serves on the editorial boards of the Journal of Surgical Oncology, the Journal of Cancer, and Clinical Medicine Insights: Oncology and as the associate editor-in-chief of several other journals.

Steven White is the CBO of LumaBridge and helped found the company (as Cancer Insight) in 2014. After graduating from Trinity University, Mr. White practiced as an accountant in tax and assurance services for several years. He later went on to earn his law license and practiced as a business and contracts attorney in San Antonio, Texas. Since helping found LumaBridge, he has worked closely with teams across all areas of the company, giving him a deep appreciation for their work and the company’s mission.

During his time with LumaBridge, Mr. White has helped support both the company’s academic background and its growth by contributing to commercial development. He believes the most important thing LumaBridge does is act as a development partner to support promising therapies for patients.

Todd Lehman

Todd brings almost 20 years of experience in client services and in commercial and clinical operations to LumaBridge as the head of business development. Prior to joining LumaBridge, Todd held various leadership roles in operations and portfolio management with a focus on the biotech customer while at PPD, part of Thermo Fisher Scientific. He got his start in the industry in 2004 with Rx Development Resources, a start-up niche CRO that transformed into Sirion Therapeutics, a small biotech. Sirion in-licensed 5 ex-US assets and received 2 marketing approvals over a 3-year period.    

Todd has experience across several therapeutic areas, with focus in oncology and ophthalmology, and holds a bachelor's degree in chemical engineering and a master's in biomedical engineering from the University of South Florida. Prior to his time in clinical research, Todd spent about 10 years in retail and b2b commodity sales.